Applicants: Philip U. Livingston and Friedhelm Helling

Serial No.: 08/196,154

Filed: November 16, 1995

Page 2

in the Claims

Please amend claims 97, 111, and 113 as follows.

A marked-up version of the amended claims, wherein the deleted material is in brackets and the inserted material is underlined, is attached hereto as **Exhibit A**.

97. (twice amended) A composition which comprises:

a) a conjugate of i)a GM2 ganglioside derivative which comprises an unaltered ogliosaccharide part and an altered ceramide portion comprising a sphingosine base, to ii) Keyhole Limpet Hemocyanin, comprising an e-aminolysyl group:

h) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and

c) a pharmaceutically acceptable carrier;

the relative amounts of such conjugate and such suponin being effect we to stimulate or enhance antibody production in a subject, wherein in the conjugate the ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin through a C-1 carbon of the sphingosine base of the ceramide postion of the quaglioside derivative to the e-aminolysyl group of Keyhole Limpet Hemocyanin, wherein the C-4 carbon is present in a CH, group.

Ab.

H'

Applicants:

Philip C. Livingston and Friedhelm Helling

Serial No.:

08/196,154

Filed

November 16, 1995

Page 3

-\111. (twice amended) A method of stimulating or enhancing antibody\production is a subject which comprises administering to the subject an effective amount of a compositton which comprises:

a) a conjugate of i) \a GM2 ganglioside derivative which comprises an unpltered ogliosaccharide part and an altered ceramide portion comprising a sphingosine hase, to ii) Kcyhole Limpet Hemocyanin comprising an e-aminolykyl group;

- b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and
- c) a pharmacentically acceptable carrier;

the relative amounts of such conjugate and such saponin being effective to stimulate or enhance antibody production in the \subject,

wherein in the conjugate the ganglicaide derivative is covalencly bound to Keyhole Limpet Hemocyanin through a C-4 carbon of the sphingosine base of the ceramide portion of the ganglioside derivative to Keyhole bf e-aminolysyl group the Hemocyanin, wherein the C-4 carbon is present in a CIl2 group, wo as to thereby stimulate or enhance antibody production in the subject.

A 12

Applicants:

Philip C. Livingston and Friedhelm Helling

Serial No.:

08/196,154

filed

November 16, 1995

Page 4

--1113. (Twice amanded) A method of treating a cancer in a subject which comprises administering to the subject an Affective cancer treating amount of a composition which comprises:

- a) a conjugare of i) a GM2 ganglioside derivative which comprises an unaltered ogliosaccharide part and an altered ceramide portion comprising a sphingosine base to ii) Keyhole Limpet Hemocyanin comprising an e-aminolysyl group;
- b) a saponin derivable from the bark of a Quillaja saponaria Molina thee; and
- c) a pharmacoutically acceptable carrier;

the relative amounts of such conjugate and such saponin being effect to stimulate or enhance antibody production in a subject,

wherein in the conjugate the ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin through a C-4 carbon of the sphingosine base of the ceramido portion of the ganglioside derivative to ε -aminolysyl group of Kcyhole the Hemocyanin, wherein the q-4 carbon is present in a CH, group, so as to thereby treat the cancer in the subject. f-

Please cancel claims 98 and 99 without prejudice.